BioNexus Gene Lab Balance Sheet Statement

BGLC $2.1 0.0 0.0%

24/02/21

Highly Speculative, Small Cap, Style Neutral

Market Cap £258.1m

Enterprise Value £257.9m

Revenue £59.6k

Quality

Value

Momentum

StockRank™

To unlock BioNexus Gene Lab's balance sheet statement please upgrade your membership.

	2017	2018	2019
Period End:	2017-12-31	2018-12-31	2019-12-31
Period Length:	0	0	0
Currency:	USD	USD	USD

Cash
Cash and Short Term Investments
Total Receivables, Net
Total Inventory
Other Current Assets, Total
Total Current Assets

Property/Plant/Equipment, Total - Gross
Accumulated Depreciation, Total
Property/Plant/Equipment, Total - Net
Long Term Investments
Total Assets

Accounts Payable
Accrued Expenses
Notes Payable/Short Term Debt
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total
Total Current Liabilities

Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Other Liabilities, Total
Total Liabilities

Common Stock
Additional Paid-In Capital
Retained Earnings (Accumulated Deficit)
Other Equity, Total
Total Equity

Total Liabilities & Shareholders’ Equity
Total Common Shares Outstanding

Unlock Stockopedia Premium for free!

See what it can do for your stockpicking and portfolio at no expense.